研究单位：[1]RenJi Hospital[2]The First Affiliated Hospital, Zhejiang University School of Medicine,Zhejiang,China[3]Xuanwu Hospital, Capital Medical University,Beijing,China[4]The Second Affiliated Hospital of Guangzhou Medical University,Guangdong,China[5]The Affiliated Hospital of Guizhou Medical University,Guizhou,China[6]Nanjing Brain Hospital,Jiangsu,China[7]Nanjing Drum Tower Hospital,Jiangsu,China[8]Nantong First People''s Hospital,Jiangsu,China[9]Huadong Hospital, Fudan University,Shanghai,China[10]Renji Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China[11]Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China[12]Shanghai Mental Health Center,Shanghai,China[13]West China Hospital of Sichuan University,Sichuan,China[14]Tianjin Medical University General Hospital,Tianjin,China[15]Jinhua Central Hospital,Zhejiang,China[16]Ningbo Second Hospital,Zhejiang,China
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.
